Monomorphic epitheliotropic intestinal T cell lymphoma

Monomorphic epitheliotropic intestinal T cell lymphoma
Monomorphic epitheliotropic intestinal T cell lymphoma
Other names	Enteropathy-associated T cell lymphoma, type II
Specialty	Hematology and Oncology
Symptoms	GI tract symptoms
Duration	Rapidly progressive
Causes	Malignant T cells
Prognosis	Poor

Last updated April 05, 2024

Monomorphic epitheliotropic intestinal T cell lymphoma (MEITL) (formerly termed enteropathy-associated T cell lymphoma, type II) is an extremely rare peripheral T-cell lymphoma that involves the malignant proliferation of a type of lymphocyte, the T cell, in the gastrointestinal tract (i.e. GI tract).^[1] Over time, these T cells commonly spread throughout the mucosal lining of a portion of the GI tract^[2] (particularly the jejunum and ileum of the small intestine^[3]), lead to GI tract nodules and ulcerations, and cause symptoms such as abdominal pain, weight loss, diarrhea, obstruction, bleeding, and/or perforation.^[2]

In 2008, the World Health Organization defined a specific type of lymphoma, enteropathy-associated T cell lymphoma (EATL), as having two different types: EATL type I, a lymphoma occurring in patients with the chronic, autoimmune GI tract disorder, celiac disease, and EATL type II, a similar bowel lymphoma that was not associated with celiac disease. However, subsequent studies found significant clinical, pathologic, and pathophysiological differences between these two types of lymphoma. Consequently, the World Health Organization (2016) redefined these lymphomas as separate entities, terming the celiac disease-associated lymphoma as enteropathy-associated T cell lymphoma (EATL) and the lymphoma not associated with celiac disease as monomorphic epitheliotropic intestinal T cell lymphoma (MEITL).^[4] MEITL is only 1/5 to 1/10 as common as EATL.^[5] The Organization (2016) also termed a third type of intestinal T cell lymphoma that could not be classified as ATL or MEITL as intestinal T cell lymphoma, not otherwise specified.^[6]

MEITL is a highly aggressive GI tract lymphoma^[7] which typically has had very short survival times following its diagnosis.^[2] The disease often occurs in elderly patients who are afflicted with other ailments and consequently have little tolerance for the standard chemotherapy regimens that are used to treat other types of lymphomas. Moreover, these therapeutic regimens have shown little effectiveness in treating MEITL. To date, the best but still only marginally effective therapeutic interventions for the disease have been treatments that incorporate hematopoietic stem cell transplantation into chemotherapy plus surgical (when needed to treat local bowel issues such as obstruction or perforation) regimens.^[3]

Presentation

MEITL has been seen more often in Asians and individuals of Hispanic descent, in males (male to female ratio of ~2 to 1), and in mature or elderly individuals (median age ~60 years).^[2] Patients may present with irregular bowel movements, abdominal pain, hematochezia (i.e. the anal passage of fresh blood),^[2] B symptoms (i.e. fever, night sweats, weight loss), loss of appetite,^[5] and/or bowel perforations and/or obstructions.^[2]

Pathophysiology

The malignant T cells in MEITL can be identified by: their expression of cluster of differentiation (i.e. CD) cell surface molecules CD3, CD8, and CD56; by their failure to express CD4, CD5, or CD30; and, in particular, by their overexpression of megakaryocyte-associated tyrosine kinase. They are not infected with the Epstein-Barr virus and therefore do not express this virus's products (e.g. EBER1 or EBER2).^[3] In most individuals with the disease, these T cells are γδ rather than αβ T-cells based on their expression of γδ rather than αβ T-cell receptors. They also commonly express cytotoxic T cell activation markers such as TIA1, granzyme B, and perforin and therefore may have derived from or be related to cytotoxic T cell lymphocytes. However, in up to 25% of cases the malignant cells in MEITL also express markers of B cell lymphocytes. Detection of these "tumor marker" molecules on or in the lymphocytes of diseased tissues is critical for diagnosing MEITL; however, it does not clearly establish the original type of lymphocytes which became MEITL's malignant cells. This issue requires further studies.^[8]

MEITL is thought to arise from intraepithelial lymphocytes that normally reside in the epithelial lining of the GI tract and over time acquire abnormalities that promote their survival, proliferation, avoidance of the immune system, and thereby malignancy. These cells are not infected with the Epstein-Barr virus and therefore have not become malignant as a consequence of this virus's malignancy-producing effects on lymphocytes as it does in other types of GI tract lymphomas. Rather, the malignant T cells in MEITL bear various genetic abnormalities that may promote their malignancy. Restriction fragment length polymorphism studies indicate that these cells have abnormal gains in minisatellites, i.e. repetitive small DNA sequences, in chromosomes 1, 5, 7, 8, 9, 13, 16, and 18. These minisatellites disrupt the production of some genes but the potential relevancies of these disruptions have not been defined.^[4] Genetic abnormalities commonly found in MEITL that do have potentially pro-malignant effects include:

Losses on the short (i.e. "p") arm around position 21.3 on one of the two inherited chromosomes 9. This results in a loss of heterozygosity for two genes, the CDKN2A gene which encodes cyclin-dependent kinase Inhibitor 2A, a protein that regulates cell proliferation and the CDKN2B gene which encodes multiple tumor suppressor 2, a protein that regulates cell death and tumor formation.^[4]
A similar loss of heterzygosity on the p arm of chromosome 17 at positions 12 through 13.2. This results in the loss of one of the inherited TP53 genes. TP53 encodes tumor suppressor p53, a protein that regulates cell proliferation, death, and tumor formation.^[4]
Mutations in JAK-STAT signaling pathway genes (i.e. JAK3 and STAT5B ). This pathway regulates cell proliferation, death, and tumor formation.^[4]
Mutations in MAPK/ERK pathway genes (i.e. BRAF and KRAS ). This pathway regulates cellular proliferation.^[4]
Mutations in the GNA12 gene. This gene encodes Gα12, a G alpha subunit that is required for stimuli to regulate cell function through Gα12-coupled receptors.
Mutations in the chromatin remodeling gene, SETD2 . This gene encodes SET domain containing 2, a protein that acts to reduce the occurrence of gene deletions and tumor formation.^[4]
Mutations in the CREBBP gene. This gene encodes CREB-binding protein, a protein that activates various transcription factors some of which are implicated in tumor development.^[4]
Increased expression of the Myc proto-oncogene. When over-expressed, this genes product, the transcription factor, MYC, stimulates other genes to make their products, some of which stimulate cell proliferation.^[8]

Further studies are required to determine which, if any, of these genetic abnormalities play a role in the development and/or progression of MEITL and therefore are therapeutic targets for treating the disease.^[4]

Diagnosis

The symptoms of MEITL are generally non-specific. The diagnosis depends on endoscopic findings in the GI tract, histological findings on biopsied specimens from involved areas of the GI tract, evidence of disease involvement outside of the GI tract, and the differentiation of MEITL from other GI tract lymphomas and benign lymphoproliferative diseases. Endoscopy typically shows multiple raised and/or ulcerated lesions involving the jejunum or ileum, and less commonly, the duodenum, stomach, or colon.^[3] These lesions may occur at multiple sites or spread throughout large areas of the GI tract. Biopsied tissues show abnormally broad intestinal villi caused by the infiltration of sheets of uniformly-sized lymphocytes. These lymphocytes may also infiltrate and disrupt the architecture of nearby intestinal crypts and the epithelial lining. Unlike celiac disease-associated EATL, the lesions usually have little evidence of inflammatory cells (particularly lymphoplasmacytoid cells, i.e. cells showing a mixture of B cell and plasma cell morphological features) or of infiltration of the epithelium lining by the types of lymphocytes seen in celiac disease.^[2] The lymphocytes in these lesions are T cells expressing the marker molecules and genetic abnormalities given in the above Pathophysiology section.^[3]^[4]^[8] CT scans commonly reveal involvement of mesenteric lymph nodes.^[2] Advanced cases have involvement of the bone marrow ^[5] and/or dissemination into other organs.^[9]

Differential diagnosis

MEITL must be differentiated from the following GI tract disorders with which it shares some common features.

Enteropathy-associated T cell lymphoma (EATL): By definition, MEITL differs from EATL in that EATL specifically occurs in patients with celiac disease. In cases where the presence of celiac disease is not obvious, EATL is differentiated from MEITL by: its occurrence primarily in individuals of Northern European descent, the presence of inflammatory plasmacytoid cells in its lesions,^[5] by the tendency of its lesions to consist of γδ rather than αβ T-cell receptor-expressing lymphocytes, by its T cells that express CD30 but not CD56 or megakaryocyte-associated tyrosine kinase.^[8] and by most (95%) individuals with EATL being of either the HLA-DQ2 or HLA-DQ8 rather than other HLA-DQ haplotypes.^[8]
Extranodal NK/T cell lymphoma, nasal type (ENKTCL-NT): ENKTCL-NT is a lymphoma that usually involves nasal and oropharyngeal airways but may involve lower areas of the GI tract with lesions that mimic MEITL. Unlike MEITL, it is more commonly due to the proliferation of NK rather than T cell lymphocytes, in all cases is caused by lymphocytes that are infected with the Epstein-Barr virus and therefore express this virus's products,^[10] and in almost all cases is caused by lymphocytes that do not express CD3 and have not rearranged their T cell receptors.^[7]
Anaplastic large cell lymphoma, ALK positive (ALCL,ALK+): ALCL,ALK+ is a subtype of anaplastic large cell lymphoma. It commonly involves the malignant proliferation of T cells in tissues outside of the GI tract but in some cases the disease involves primarily the GI tract.^[7] Unlike MEITL, ALCL,ALK+ occurs most commonly in young individuals and individuals from Western Countries and most often involves tissue infiltrates of large, anaplastic-appearing T cells which express a fusion gene involving the ALK gene (which encodes Anaplastic lymphoma kinase),^[11] but do not express CD3, CD8, or CD56.^[7]
Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS): PTCL-NOS is a heterogenous group of T cell lymphomas that involves lymph nodes, bone marrow, liver, spleen, and/or GI tract. Rarely this lymphoma may present in the GI tract without overt evidence of involvement of other tissues. Unlike MEITL, the T cells in this disease exhibit genetic abnormalities in TET2, IDH2, DNMT3A, RHOA, CD28 , and VAV1 genes^[12] but in general do not have the genetic abnormalities or express the molecular markers found in MEITL.^[7]
Natural killer cell enteropathy (NKCE): NKCE is a benign disease of the GI tract which has GI tract lesions and symptoms that mimic MEITL. Unlike MEITL, NKCE involves the proliferation of non-clonal NK cell lymphocytes which exhibit activation markers (e.g. granzyme B, perforin, and T-cell intracellular antigen-1) but no genetic abnormalities.
Indolent T cell lymphoproliferative disorder of the gastrointestinal tract (ITCLD-GT): ITCLD-GT is a generally benign disease of the GI tract that has in some cases progressed to an aggressive lymphoma. It presents with clinical signs and GI tract lesions which may mimic MEITL.^[8]^[2] These lesions involve infiltrations of T-cells that unlike the T cells in MEITL proliferate slowly, are homogenously small-sized, CD56-negative, may express CD4,^[8] and usually do not express CD8.^[5]

Treatment

There is no standard treatment for MEITL. Most individuals have been treated by surgical resections of involved areas with or without anthracycline-based chemotherapy. In these cases, responses have been short-lived and/or poor with 1 year overall survival rates, 1 year progression free survival rates, and median survival times of 36%, 21%, and 7 months, respectively.^[5] A retrospective study of patients treated with resection, chemotherapy and autologous hematopoietic stem cell transplantation had a higher 1-year and 5-year overall survival (100%, 33%) compared to one-year survival (73%) and five-year survival (14%) without transplantation; a second retrospective study supported the usefulness of transplantation in that high-dose lymphoma chemotherapy followed by transplantation and standard-dose lymphoma chemotherapy with or without surgical resection increased 5-year overall survival from 22 to 60% and 5-year disease progression-free survival from 22 to 52%.^[13] While further studies, particularly randomized controlled trials, are needed to investigate the best treatments for MEITL, the use of lymphoma chemotherapy, hematopoietic stem cell transplantation, and, where needed, surgical resections are the currently recommended treatments for MEITL.^[3]

Related Research Articles

Lymphoma is a group of blood and lymph tumors that develop from lymphocytes. The name typically refers to just the cancerous versions rather than all such tumours. Signs and symptoms may include enlarged lymph nodes, fever, drenching sweats, unintended weight loss, itching, and constantly feeling tired. The enlarged lymph nodes are usually painless. The sweats are most common at night.

Tumors of the hematopoietic and lymphoid tissues or tumours of the haematopoietic and lymphoid tissues are tumors that affect the blood, bone marrow, lymph, and lymphatic system. Because these tissues are all intimately connected through both the circulatory system and the immune system, a disease affecting one will often affect the others as well, making aplasia, myeloproliferation and lymphoproliferation closely related and often overlapping problems. While uncommon in solid tumors, chromosomal translocations are a common cause of these diseases. This commonly leads to a different approach in diagnosis and treatment of hematological malignancies. Hematological malignancies are malignant neoplasms ("cancer"), and they are generally treated by specialists in hematology and/or oncology. In some centers "hematology/oncology" is a single subspecialty of internal medicine while in others they are considered separate divisions. Not all hematological disorders are malignant ("cancerous"); these other blood conditions may also be managed by a hematologist.

Anaplastic large-cell lymphoma (ALCL) refers to a group of non-Hodgkin lymphomas in which aberrant T cells proliferate uncontrollably. Considered as a single entity, ALCL is the most common type of peripheral lymphoma and represents ~10% of all peripheral lymphomas in children. The incidence of ALCL is estimated to be 0.25 cases per 100,000 people in the United States of America. There are four distinct types of anaplastic large-cell lymphomas that on microscopic examination share certain key histopathological features and tumor marker proteins. However, the four types have very different clinical presentations, gene abnormalities, prognoses, and/or treatments.

Follicular lymphoma (FL) is a cancer that involves certain types of white blood cells known as lymphocytes. The cancer originates from the uncontrolled division of specific types of B-cells known as centrocytes and centroblasts. These cells normally occupy the follicles in the germinal centers of lymphoid tissues such as lymph nodes. The cancerous cells in FL typically form follicular or follicle-like structures in the tissues they invade. These structures are usually the dominant histological feature of this cancer.

Primary effusion lymphoma (PEL) is classified as a diffuse large B cell lymphoma. It is a rare malignancy of plasmablastic cells that occurs in individuals that are infected with the Kaposi's sarcoma-associated herpesvirus. Plasmablasts are immature plasma cells, i.e. lymphocytes of the B-cell type that have differentiated into plasmablasts but because of their malignant nature do not differentiate into mature plasma cells but rather proliferate excessively and thereby cause life-threatening disease. In PEL, the proliferating plasmablastoid cells commonly accumulate within body cavities to produce effusions, primarily in the pleural, pericardial, or peritoneal cavities, without forming a contiguous tumor mass. In rare cases of these cavitary forms of PEL, the effusions develop in joints, the epidural space surrounding the brain and spinal cord, and underneath the capsule which forms around breast implants. Less frequently, individuals present with extracavitary primary effusion lymphomas, i.e., solid tumor masses not accompanied by effusions. The extracavitary tumors may develop in lymph nodes, bone, bone marrow, the gastrointestinal tract, skin, spleen, liver, lungs, central nervous system, testes, paranasal sinuses, muscle, and, rarely, inside the vasculature and sinuses of lymph nodes. As their disease progresses, however, individuals with the classical effusion-form of PEL may develop extracavitary tumors and individuals with extracavitary PEL may develop cavitary effusions.

T-cell lymphoma is a rare form of cancerous lymphoma affecting T-cells. Lymphoma arises mainly from the uncontrolled proliferation of T-cells and can become cancerous.

Intravascular lymphomas (IVL) are rare cancers in which malignant lymphocytes proliferate and accumulate within blood vessels. Almost all other types of lymphoma involve the proliferation and accumulation of malignant lymphocytes in lymph nodes, other parts of the lymphatic system, and various non-lymphatic organs but not in blood vessels.

Diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells, a type of lymphocyte that is responsible for producing antibodies. It is the most common form of non-Hodgkin lymphoma among adults, with an annual incidence of 7–8 cases per 100,000 people per year in the US and UK. This cancer occurs primarily in older individuals, with a median age of diagnosis at ~70 years, although it can occur in young adults and, in rare cases, children. DLBCL can arise in virtually any part of the body and, depending on various factors, is often a very aggressive malignancy. The first sign of this illness is typically the observation of a rapidly growing mass or tissue infiltration that is sometimes associated with systemic B symptoms, e.g. fever, weight loss, and night sweats.

Richter's transformation (RT), also known as Richter's syndrome, is the conversion of chronic lymphocytic leukemia (CLL) or its variant, small lymphocytic lymphoma (SLL), into a new and more aggressively malignant disease. CLL is the circulation of malignant B lymphocytes with or without the infiltration of these cells into lymphatic or other tissues while SLL is the infiltration of these malignant B lymphocytes into lymphatic and/or other tissues with little or no circulation of these cells in the blood. CLL along with its SLL variant are grouped together in the term CLL/SLL.

Enteropathy-associated T-cell lymphoma (EATL), previously termed enteropathy-associated T-cell lymphoma, type I and at one time termed enteropathy-type T-cell lymphoma (ETTL), is a complication of coeliac disease in which a malignant T-cell lymphoma develops in areas of the small intestine affected by the disease's intense inflammation. While a relatively rare disease, it is the most common type of primary gastrointestinal T-cell lymphoma.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. It was initially regarded as a form of lymphocyte-derived cutaneous lymphoma and alternatively named CD4+CD56+ hematodermic tumor, blastic NK cell lymphoma, and agranular CD4+ NK cell leukemia. Later, however, the disease was determined to be a malignancy of plasmacytoid dendritic cells rather than lymphocytes and therefore termed blastic plasmacytoid dendritic cell neoplasm. In 2016, the World Health Organization designated BPDCN to be in its own separate category within the myeloid class of neoplasms. It is estimated that BPDCN constitutes 0.44% of all hematological malignancies.

Marginal zone lymphomas, also known as marginal zone B-cell lymphomas (MZLs), are a heterogeneous group of lymphomas that derive from the malignant transformation of marginal zone B-cells. Marginal zone B cells are innate lymphoid cells that normally function by rapidly mounting IgM antibody immune responses to antigens such as those presented by infectious agents and damaged tissues. They are lymphocytes of the B-cell line that originate and mature in secondary lymphoid follicles and then move to the marginal zones of mucosa-associated lymphoid tissue (MALT), the spleen, or lymph nodes. Mucosa-associated lymphoid tissue is a diffuse system of small concentrations of lymphoid tissue found in various submucosal membrane sites of the body such as the gastrointestinal tract, mouth, nasal cavity, pharynx, thyroid gland, breast, lung, salivary glands, eye, skin and the human spleen.

Extranodal NK/T-cell lymphoma, nasal type (ENKTCL-NT) is a rare type of lymphoma that commonly involves midline areas of the nasal cavity, oral cavity, and/or pharynx At these sites, the disease often takes the form of massive, necrotic, and extremely disfiguring lesions. However, ENKTCL-NT can also involve the eye, larynx, lung, gastrointestinal tract, skin, and various other tissues. ENKTCL-NT mainly affects adults; it is relatively common in Asia and to lesser extents Mexico, Central America, and South America but is rare in Europe and North America. In Korea, ENKTCL-NT often involves the skin and is reported to be the most common form of cutaneous lymphoma after mycosis fungoides.

Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC). It acts as an ALK and ROS1 inhibitor.

Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm of the mesodermal cells that form the connective tissues which support virtually all of the organs and tissues of the body. IMT was formerly termed inflammatory pseudotumor. Currently, however, inflammatory pseudotumor designates a large and heterogeneous group of soft tissue tumors that includes inflammatory myofibroblastic tumor, plasma cell granuloma, xanthomatous pseudotumor, solitary mast cell granuloma, inflammatory fibrosarcoma, pseudosarcomatous myofibroblastic proliferation, myofibroblastoma, inflammatory myofibrohistiocytic proliferation, and other tumors that develop from connective tissue cells. Inflammatory pseudotumour is a generic term applied to various neoplastic and non-neoplastic tissue lesions which share a common microscopic appearance consisting of spindle cells and a prominent presence of the white blood cells that populate chronic or, less commonly, acute inflamed tissues.

Epstein–Barr virus–associated lymphoproliferative diseases are a group of disorders in which one or more types of lymphoid cells, i.e. B cells, T cells, NK cells, and histiocytic-dendritic cells, are infected with the Epstein–Barr virus (EBV). This causes the infected cells to divide excessively, and is associated with the development of various non-cancerous, pre-cancerous, and cancerous lymphoproliferative disorders (LPDs). These LPDs include the well-known disorder occurring during the initial infection with the EBV, infectious mononucleosis, and the large number of subsequent disorders that may occur thereafter. The virus is usually involved in the development and/or progression of these LPDs although in some cases it may be an "innocent" bystander, i.e. present in, but not contributing to, the disease.

Natural killer cell enteropathy, also termed NK cell enteropathy (NKCE), and a closely related disorder, lymphomatoid gastropathy (LG), are non-malignant diseases in which one type of lymphocyte, the natural killer cell, proliferates excessively in the gastrointestinal tract. This proliferation causes red, sore-like spots, raised lesions, erosions, and ulcers in the mucosal layer surrounding the GI tract lumen. Both disorders cause either no or only vague symptoms of GI tract disturbances such as nausea, vomiting, and bleeding.

Indolent T cell lymphoproliferative disorder of the gastrointestinal tract or Indolent T cell lymphoproliferative disorder of the GI tract (ITCLD-GT) is a rare and recently recognized disorder in which mature T cell lymphocytes accumulation abnormally in the gastrointestinal tract. This accumulation causes various lesions in the mucosal layer lining the GI tract. Individuals with ITCLD-GT commonly complain of chronic GI tract symptoms such as nausea, vomiting, diarrhea, abdominal pain, and rectal bleeding.

Duodenal-type follicular lymphoma (DFL) is a form of lymphoma in which certain lymphocyte types, the B-cell-derived centrocytes and centroblasts, form lymph node follicle-like structures principally in the duodenum and other parts of the small intestine. It is an indolent disease which on rare occasions progresses to a more aggressive lymphoma that spreads beyond these originally involved sites.

T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a malignancy of B cells. B-cells are lymphocytes that normally function in the humoral immunity component of the adaptive immune system by secreting antibodies that, for example, bind to and neutralize invasive pathogens. Among the various forms of B-cell lymphomas, THRLBCL is a rarely occurring subtype of the diffuse large B-cell lymphomas (DLBCL). DLBCL are a large group of lymphomas that account for ~25% of all non-Hodgkin lymphomas worldwide. THRLBCL is distinguished from the other DLBCL subtypes by the predominance of non-malignant T-cell lymphocytes and histiocytes over malignant B-cells in its tumors and tissue infiltrates.

References

↑ Zhao L, Yang Y, Zhang Y (June 2018). "Type II enteropathy-associated t-cell lymphoma: A case report and literature review". Nigerian Journal of Clinical Practice. 21 (6): 812–815. doi: 10.4103/njcp.njcp_280_17 . PMID 29888733. S2CID 47006447.
1 2 3 4 5 6 7 8 9 Weindorf SC, Smith LB, Owens SR (November 2018). "Update on Gastrointestinal Lymphomas". Archives of Pathology & Laboratory Medicine. 142 (11): 1347–1351. doi: 10.5858/arpa.2018-0275-RA . PMID 30407861.
1 2 3 4 5 6 Tian S, Xiao SY, Chen Q, Liu H, Ping J (2019). "Monomorphic epitheliotropic intestinal T-cell lymphoma may mimic intestinal inflammatory disorders". International Journal of Immunopathology and Pharmacology. 33: 2058738419829387. doi:10.1177/2058738419829387. PMC 6376542 . PMID 30757928.
1 2 3 4 5 6 7 8 9 10 Chander U, Leeman-Neill RJ, Bhagat G (August 2018). "Pathogenesis of Enteropathy-Associated T Cell Lymphoma". Current Hematologic Malignancy Reports. 13 (4): 308–317. doi:10.1007/s11899-018-0459-5. PMID 29943210. S2CID 49430640.
1 2 3 4 5 6 Ondrejka S, Jagadeesh D (December 2016). "Enteropathy-Associated T-Cell Lymphoma". Current Hematologic Malignancy Reports. 11 (6): 504–513. doi:10.1007/s11899-016-0357-7. PMID 27900603. S2CID 13329863.
↑ Matutes E (May 2018). "The 2017 WHO update on mature T- and natural killer (NK) cell neoplasms". International Journal of Laboratory Hematology. 40 (Suppl 1): 97–103. doi: 10.1111/ijlh.12817 . PMID 29741263.
1 2 3 4 5 Tang XF, Yang L, Duan S, Guo H, Guo QN (December 2018). "Intestinal T-cell and NK/T-cell lymphomas: A clinicopathological study of 27 Chinese patients". Annals of Diagnostic Pathology. 37: 107–117. doi:10.1016/j.anndiagpath.2018.10.004. PMID 30317149. S2CID 52979874.
1 2 3 4 5 6 7 Foukas PG, de Leval L (January 2015). "Recent advances in intestinal lymphomas". Histopathology. 66 (1): 112–36. doi:10.1111/his.12596. PMID 25639480. S2CID 20669863.
↑ Moffitt AB, Ondrejka SL, McKinney M, Rempel RE, Goodlad JR, Teh CH, Leppa S, Mannisto S, Kovanen PE, Tse E, Au-Yeung RK, Kwong YL, Srivastava G, Iqbal J, Yu J, Naresh K, Villa D, Gascoyne RD, Said J, Czader MB, Chadburn A, Richards KL, Rajagopalan D, Davis NS, Smith EC, Palus BC, Tzeng TJ, Healy JA, Lugar PL, Datta J, Love C, Levy S, Dunson DB, Zhuang Y, Hsi ED, Dave SS (May 2017). "Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2". The Journal of Experimental Medicine. 214 (5): 1371–1386. doi:10.1084/jem.20160894. PMC 5413324 . PMID 28424246.
↑ Farrell PJ (2019). "Epstein-Barr Virus and Cancer". Annual Review of Pathology. 14: 29–53. doi:10.1146/annurev-pathmechdis-012418-013023. PMID 30125149. S2CID 52051261.
↑ Xing X, Feldman AL (January 2015). "Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous". Advances in Anatomic Pathology. 22 (1): 29–49. doi:10.1097/PAP.0000000000000047. PMID 25461779. S2CID 44892063.
↑ Broccoli A, Zinzani PL (March 2017). "Peripheral T-cell lymphoma, not otherwise specified". Blood. 129 (9): 1103–1112. doi: 10.1182/blood-2016-08-692566 . PMID 28115372.
↑ Gentille C, Qin Q, Barbieri A, Ravi PS, Iyer S (2017). "Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges". ecancermedicalscience. 11: 771. doi:10.3332/ecancer.2017.771. PMC 5636209 . PMID 29062389.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[pmid29888733-1] Zhao L, Yang Y, Zhang Y (June 2018). "Type II enteropathy-associated t-cell lymphoma: A case report and literature review". Nigerian Journal of Clinical Practice. 21 (6): 812–815. doi: 10.4103/njcp.njcp_280_17 . PMID 29888733. S2CID 47006447.

[pmid30407861-2] 1 2 3 4 5 6 7 8 9 Weindorf SC, Smith LB, Owens SR (November 2018). "Update on Gastrointestinal Lymphomas". Archives of Pathology & Laboratory Medicine. 142 (11): 1347–1351. doi: 10.5858/arpa.2018-0275-RA . PMID 30407861.

[pmid30757928-3] 1 2 3 4 5 6 Tian S, Xiao SY, Chen Q, Liu H, Ping J (2019). "Monomorphic epitheliotropic intestinal T-cell lymphoma may mimic intestinal inflammatory disorders". International Journal of Immunopathology and Pharmacology. 33: 2058738419829387. doi:10.1177/2058738419829387. PMC 6376542 . PMID 30757928.

[pmid29943210-4] 1 2 3 4 5 6 7 8 9 10 Chander U, Leeman-Neill RJ, Bhagat G (August 2018). "Pathogenesis of Enteropathy-Associated T Cell Lymphoma". Current Hematologic Malignancy Reports. 13 (4): 308–317. doi:10.1007/s11899-018-0459-5. PMID 29943210. S2CID 49430640.

[pmid27900603-5] 1 2 3 4 5 6 Ondrejka S, Jagadeesh D (December 2016). "Enteropathy-Associated T-Cell Lymphoma". Current Hematologic Malignancy Reports. 11 (6): 504–513. doi:10.1007/s11899-016-0357-7. PMID 27900603. S2CID 13329863.

[pmid29741263-6] Matutes E (May 2018). "The 2017 WHO update on mature T- and natural killer (NK) cell neoplasms". International Journal of Laboratory Hematology. 40 (Suppl 1): 97–103. doi: 10.1111/ijlh.12817 . PMID 29741263.

[pmid30317149-7] 1 2 3 4 5 Tang XF, Yang L, Duan S, Guo H, Guo QN (December 2018). "Intestinal T-cell and NK/T-cell lymphomas: A clinicopathological study of 27 Chinese patients". Annals of Diagnostic Pathology. 37: 107–117. doi:10.1016/j.anndiagpath.2018.10.004. PMID 30317149. S2CID 52979874.

[pmid25639480-8] 1 2 3 4 5 6 7 Foukas PG, de Leval L (January 2015). "Recent advances in intestinal lymphomas". Histopathology. 66 (1): 112–36. doi:10.1111/his.12596. PMID 25639480. S2CID 20669863.

[pmid28424246-9] Moffitt AB, Ondrejka SL, McKinney M, Rempel RE, Goodlad JR, Teh CH, Leppa S, Mannisto S, Kovanen PE, Tse E, Au-Yeung RK, Kwong YL, Srivastava G, Iqbal J, Yu J, Naresh K, Villa D, Gascoyne RD, Said J, Czader MB, Chadburn A, Richards KL, Rajagopalan D, Davis NS, Smith EC, Palus BC, Tzeng TJ, Healy JA, Lugar PL, Datta J, Love C, Levy S, Dunson DB, Zhuang Y, Hsi ED, Dave SS (May 2017). "Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2". The Journal of Experimental Medicine. 214 (5): 1371–1386. doi:10.1084/jem.20160894. PMC 5413324 . PMID 28424246.

[pmid30125149-10] Farrell PJ (2019). "Epstein-Barr Virus and Cancer". Annual Review of Pathology. 14: 29–53. doi:10.1146/annurev-pathmechdis-012418-013023. PMID 30125149. S2CID 52051261.

[pmid25461779-11] Xing X, Feldman AL (January 2015). "Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous". Advances in Anatomic Pathology. 22 (1): 29–49. doi:10.1097/PAP.0000000000000047. PMID 25461779. S2CID 44892063.

[pmid28115372-12] Broccoli A, Zinzani PL (March 2017). "Peripheral T-cell lymphoma, not otherwise specified". Blood. 129 (9): 1103–1112. doi: 10.1182/blood-2016-08-692566 . PMID 28115372.

[pmid29062389-13] Gentille C, Qin Q, Barbieri A, Ravi PS, Iyer S (2017). "Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges". ecancermedicalscience. 11: 771. doi:10.3332/ecancer.2017.771. PMC 5636209 . PMID 29062389.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]